Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: therapeutic cancer vaccines - igeneon

Next Previous
X
Search
Drug Profile

Research programme: therapeutic cancer vaccines - igeneon

Alternative Names: IGN 401; IGN 402; Therapeutic cancer vaccines research programme - igeneon

Latest Information Update: 05 Nov 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
  • 29 Mar 2005 igeneon Krebs Immuntherapie Forschungs und Entwicklungs AG has been acquired by Aphton Corporation
  • 03 Dec 2003 Data presented at the 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc-2003) have been added to the Cancer immunogenicity section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top